Cushman & Wakefield has been selected to advise Pfizer on its global headquarters relocation, along with the sale of its current head office space at 235 and 219 East 42nd Street, the company announced.
Pfizer has decided to sell the properties to create a new headquarters “more reflective of its culture of collaboration and innovation with best-in-class technology to support its workforce,” according to Cushman & Wakefield. It plans to find space in Manhattan.
The properties are “prime New York real estate,” the firm added.
Josh Kuriloff, Executive Vice Chairman with Cushman & Wakefield, is the lead on the Pfizer account team. Representing Pfizer from Cushman & Wakefield are: Adam Spies, Chairman Capital Markets; Doug Harmon, Chairman Capital Markets; Debra Moritz, Executive Managing Director, Global Business Consulting; Peyton Horn, Managing Director, Corporate Finance & Investment Banking; with executive oversight by John Santora, President, TriState Region. Warren Braverman, Senior Managing Director, will work as the relationship manager for the account.
